Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Ibogaine Research topic
No spam. Unsubscribe anytime.
Committee advances pathway for hospital‑based ibogaine clinical trials; amendments adopted
Summary
The Health Committee adopted amendments to the HOPE Treatment Act (HB2075), which would create a supervised research pathway for FDA‑authorized clinical trials of ibogaine for opioid use disorder and related conditions; public testimony included veterans and service‑provider groups urging research and caution on safety.
The House Health Full Committee advanced HB2075, the HOPE Treatment Act, adopting amendments that the sponsor said clarify and roll the changes into the bill. The measure would create a structured, medically supervised pathway for Tennessee institutions to participate in Food and Drug Administration‑authorized clinical trials studying ibogaine for opioid use disorder and other indications.
Sponsor comments described ibogaine as a naturally occurring psychoactive alkaloid with complex effects across several neurotransmitter systems. The sponsor said in lay terms it "helps quiet the part of the brain that drives cravings and compulsive behavior," can ease withdrawal symptoms and may create a window for durable behavioral change when paired with therapy.
Several witnesses urged careful, hospital‑based research rather than immediate legalization. Alex West, a retired Navy SEAL who said he traveled abroad for ibogaine treatment, described the experience and integration process: "The Ibogaine experience lasted about 14 hours and was physically and emotionally grueling," and he urged clinical trials so patients would not have to leave the country for care.
Ricky Harris, CEO of Tennessee Voices, noted the broader family impact of the opioid crisis: "Each year, our organization serves over 12,000 families in Tennessee across all 95 counties," and said responsible research could expand treatment choices for populations that do not respond to current options.
Peterson Wagner, representing an ibogaine nonprofit, told the committee the state could deploy hospital‑based safety measures such as cardiac screening and continuous monitoring within research protocols. The committee adopted two amendments (014072 and 014959) and rolled them into the bill. The hearing ran out of time before a final committee floor vote on final passage could be taken.
